Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
DUBLIN–(BUSINESS WIRE)–Apr. 1, 2026– Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a......





